Pfizer Cost Improvement Program Depends On COVID Outlook
Executive Summary
If COVID-19 product sales don’t meet assumptions this fall, the company said it will consider a cost reduction program to better align costs with future revenue projections.
You may also be interested in...
Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants
The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.
Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.